Sign in
CompletedNo phase

Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis

Key facts

Who runs it
University of Virginia
Where
Charlottesville, United StatesSee the site
Trial code
Status
Completed
People taking part
76 people enrolled
Started
2 Aug 2021
Ended
30 Jun 2024
Type of study
Observational, 2 groups
Treatments tested
  • Cosyntropin
Record updated
10 December 2024

Who can take part

Age
18 years to 100 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (7)Hide the full registry criteria

Who can take part

  • Age >= 18y
  • Diagnosis of cirrhosis by biopsy or compatible clinical picture
  • Experienced at least one portal decompensating event in the past and currently have a Child-Pugh B or C classification

Who cannot take part

  • Not been treated with medication known to affect the adrenal axis within the past 4 weeks (oral or IV steroids, ketoconazole, etomidate)
  • Pregnant women
  • Prisoners
  • Hospitalized at time of enrollment

Where in United States

  • University of Virginia Health SystemCharlottesville, United States

About the trial

What the trial wants to find out

This study aims to define the prevalence and potential pathophysiologic mechanisms underlying relative adrenal insufficiency (RAI) in outpatients with decompensated cirrhosis. Patients will be followed prospectively for up to two years to determine incidence of RAI, whether RAI represents a permanent or dynamic physiologic state in cirrhosis, and to determine whether RAI in this setting is associated with important clinical outcomes.

The 2 groups in the trial

  • RAI

    Subjects will be diagnosed with relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol \<9mcg/dL.

    Treatment: Cosyntropin

  • Non-RAI

    Subjects will have not have relative adrenal insufficiency as determined by administration of a standard-dose ACTH stimulation test (0.25mg Cosyntropin) and an increase in serum total cortisol \>= 9mcg/dL.

    Treatment: Cosyntropin

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Defining the Mechanisms Underlying Adrenal Dysfunction in Cirrhosis and Its Prognostic Significance
Record updated
10 December 2024